Subscribe
blackboard1965-shutterstock-com-pills-
blackboard1965 / Shutterstock.com
30 March 2016Americas

Shire wins Lialda patent trial against Watson

Biopharmaceutical company Shire has had a patent for Lialda (mesalamine) upheld in its trial against Watson Pharmaceuticals.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Shire v Watson Lialda dispute heads back to district court
10 June 2015   The US Court of Appeals for the Federal Circuit has sent a patent dispute between drugs companies Shire and Watson Pharmaceuticals back to a district court, ruling again that the lower court erroneously construed claims related to Lialda.


Editor's picks

Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024

Editor's picks

Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024

More on this story

Americas
Shire v Watson Lialda dispute heads back to district court
10 June 2015   The US Court of Appeals for the Federal Circuit has sent a patent dispute between drugs companies Shire and Watson Pharmaceuticals back to a district court, ruling again that the lower court erroneously construed claims related to Lialda.

More on this story

Americas
Shire v Watson Lialda dispute heads back to district court
10 June 2015   The US Court of Appeals for the Federal Circuit has sent a patent dispute between drugs companies Shire and Watson Pharmaceuticals back to a district court, ruling again that the lower court erroneously construed claims related to Lialda.

More features

Preventative IP for preventative pharma healthcare
Court denies Regeneron bid to halt copy of blockbuster eye drug
Interview: Klaus Grabinski, UPC Court of Appeal president
Gilead scores win in fake HIV drug dispute
Polsinelli grows roster with ex-corporate counsel
‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird
Sandoz wins $137.2m payout for lost profits in generic launch
Sanofi signs global rights deal to develop rare cancer therapy